NERVE GROWTH FACTOR IN SERUM OF CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS IS CORRELATED WITH DISEASE ACTIVITY

Cytokine ◽  
2002 ◽  
Vol 20 (3) ◽  
pp. 136-139 ◽  
Author(s):  
Kristiina Aalto ◽  
Laura Korhonen ◽  
Pekka Lahdenne ◽  
Pirkko Pelkonen ◽  
Dan Lindholm
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Nerve Growth

Disease activity-dependent expression of nerve growth factor TRKA and P75 receptors on elevated dendritic cells and peripheral leucocytes in patients with systemic lupus erythematosus

Lupus ◽  
2020 ◽  
Vol 29 (8) ◽  
pp. 970-975 ◽  
Author(s):  
Stefanie Welle ◽  
Anna M Wolf ◽  
Christian Dernbach ◽  
Ute Klarmann-Schulz ◽  
Matthias F Seidel
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Dendritic Cells ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Inflammatory Diseases ◽  
Receptor Expression ◽  
Systemic Lupus ◽  
Nerve Growth

Introduction The nervous system modulates rheumatic diseases in neurogenic inflammation (NI). Nerve growth factor (NGF) plays a pivotal role in NI and chronic nociceptive pain. However, the role of NGF in autoimmune inflammatory diseases is not well understood. The aim of this study was to analyse NGF high- (TrkA) and low-affinity (p75) receptors on all major leucocyte subsets of patients with systemic lupus erythematosus (SLE) as a potential indicator of NI. Methods A total of 13 patients were analysed by fluorescence-activated cell sorting and compared to 13 healthy control (HC) subjects. Patients were also stratified for high or low disease activity (CRP, ESR, SLEDAI, ANA, anti-dsDNA and C3/C4). Statistics included the Kruskal–Wallis test and Mann–Whitney U-test. Results When comparing patients and HC, TrkA was not differentially expressed. In contrast, p75 was increased on CD16+ and CD56+ leucocytes in patients. CD11c+ dendritic cells (DC) were in total increased in SLE. DCs were also significantly elevated in active patients. Furthermore, we found an intermediate CD11b+ population strongly expressing TrkA in patients and HC. Conclusion We demonstrate for the first time differential NGF receptor expression in SLE. The increased CD11c+ DCs might indicate additional activation in SLE.

Modification of lymphoid and brain nerve growth factor levels in systemic lupus erythematosus mice

1996 ◽  
Vol 204 (1-2) ◽  
pp. 13-16 ◽  
Author(s):  
Luisa Bracci-Laudiero ◽  
Thomas Lundeberg ◽  
Carina Stenfors ◽  
Elvar Theodorsson ◽  
Paola Tirassa ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Nerve Growth

Levels of Transforming Growth Factor-β Are Low in Systemic Lupus Erythematosus Patients with Active Disease

2010 ◽  
Vol 37 (10) ◽  
pp. 2039-2045 ◽  
Author(s):  
ANDREA BECKER-MEROK ◽  
GRO ØSTLI EILERTSEN ◽  
JOHANNES C. NOSSENT
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Growth Factor ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Transforming Growth Factor ◽  
Lymphocyte Subsets ◽  
Concomitant Treatment ◽  
Systemic Lupus ◽  
Cell Counts ◽  
Tgf Β1

Objective.Cytokines are central regulators of the immune response but the workings of this complex network in systemic lupus erythematosus (SLE) are not fully understood. We investigated a range of inflammatory and immune-modulating cytokines to determine their value as biomarkers for disease subsets in SLE.Methods.This was a cross-sectional study in 102 patients with SLE (87% women, disease duration 10.6 yrs). Circulating concentrations of interleukin 1β (IL-1β), IL-4, IL-6, IL-10, IL-12, IL-17, monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 1 (MIP-1α), MIP-1β, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and total transforming growth factor-β1 (TGF-β1) were related to disease activity (SLE Disease Activity Index; SLEDAI), lymphocyte subsets, autoantibody levels, accrued damage (Systemic Lupus International Collaborating Clinics/ACR Damage Index; SDI), and concomitant treatment.Results.Patients with SLE had lower levels of TGF-β1 (p = 0.01) and IL-1β (p = 0.0004) compared to controls. TGF-β1 levels were lower in patients with SLEDAI scores 1–10 and SDI > 3; and were correlated with CD4+, CD8+, and natural killer cell counts; and were independent of steroid or cytotoxic drug use. Treatment with cardiovascular drugs was associated with lower IL-12 levels. No consistent disease associations existed for the other cytokines investigated.Conclusion.Lower TGF-β1 was the most consistent cytokine abnormality in patients with SLE. The associations with disease activity, lymphocyte subsets, and damage suggest that TGF-β1 may be a therapeutic target of interest in SLE.

Sign in / Sign up

Export Citation Format

Share Document